ThromboGenics NV launches Jetrea ocriplasmin in the UK for the pharmacological treatment of vitreomacular adhesion (VMA)

ThromboGenics NV (Euronext Brussels: THR), a Belgian based ophthalmic biotech company has announced the EU product launch, by its partner Alcon, of ocriplasmin therapy for the treatment of symptomatic VMA. The new drug, launched in the US in mid-January 2013 under the trade name “Jetrea”, is the first pharmacological agent to be approved for VMA. The first sale of the drug in the UK triggers a EUR45M milestone payment from Alcon to ThromboGenics. The drug recently received EMA approval for the treatment of vitreomacular adhesion, including when associated with macular hole of diameter less than or equal to 400 microns.